San Diego-based mostly Viking Therapeutics marked by itself as a significant competitor during the weight loss drug marketplace in February following revealing promising facts from a mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection and in March the com